Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prove the hypothesis that the progression of renal and
cardiovascular disease is more efficiently prevented when the angiotensin II receptor blocker
valsartan is added to conventional antihypertensive therapy.
Phase:
Phase 4
Details
Lead Sponsor:
KVT-Study Group
Collaborators:
Kitasato University Showa University St. Marianna University School of Medicine Tokai University Yokohama City University